# 1 cfDNA UniFlow: A unified preprocessing pipeline for cell-free DNA

- 2 data from liquid biopsies
- 3

#### 4 Authors

- 5 Sebastian Röner<sup>1</sup>, Lea Burkard<sup>1,4</sup>, Michael R. Speicher<sup>2‡</sup>, Martin Kircher<sup>1,3</sup>
- 6 <sup>1</sup> Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany
- <sup>2</sup> Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical
   University of Graz, Graz, Austria
- 9 <sup>3</sup> Institute of Human Genetics, University Medical Center Schleswig-Holstein, University of Lübeck,
- 10 23562 Lübeck, Germany
- <sup>4</sup> University of Potsdam, Institute for Biochemistry and Biology, 14469 Potsdam, Germany
- 12 <sup>‡</sup> Deceased on Sep 24, 2023
- 13
- 14 Contact: martin.kircher@bih-charite.de

# 16 Abstract:

#### 17 Background:

Cell-free DNA (cfDNA), a broadly applicable biomarker commonly sourced from urine or blood, is
 extensively used for research and diagnostic applications. In various settings, genetic and epigenetic
 information is derived from cfDNA. However, a unified framework for its processing is lacking, limiting

21 the universal application of innovative analysis strategies and the joining of data sets.

#### 22 Findings:

Here, we describe cfDNA UniFlow, a unified, standardized, and ready-to-use workflow for processing cfDNA samples. The workflow is written in Snakemake and can be scaled from stand-alone computers to cluster environments. It includes methods for processing raw genome sequencing data as well as specialized approaches for correcting sequencing errors, filtering, and quality control. Sophisticated methods for detecting copy number alterations and estimating and correcting GC-related biases are readily incorporated. Furthermore, it includes methods for extracting, normalizing and visualizing coverage signals around user defined regions in case-control settings. Ultimately, all results and

- 30 metrics are aggregated in a unified report, enabling easy access to a wide variety of information for
- 31 further research and downstream analysis.

#### 32 Conclusions:

33 We provide an automated pipeline for processing cell-free DNA sampled from liquid biopsies, including

34 a wide variety of additional functionalities like bias correction and signal extraction. With our focus on

- 35 scalability and extensibility, we provide a foundation for future cfDNA research and faster clinical
- 36 applications.
- 37

#### 38 Keywords:

- 39 Cell-free DNA, liquid biopsies, sequence analysis, cancer detection, workflow
- 40
- 41 Issue Section:
- 42 Technical Note
- 43
- Availability and implementation: Source code and extensive documentation is available on our
   GitHub repository (<u>https://github.com/kircherlab/cfDNA-UniFlow</u>).

46

### 48 Introduction/Background

49 Cell-free DNA (cfDNA) is found in many bodily fluids like blood plasma and urine [1]. It is believed to

- 50 be primarily derived from natural degradation processes during cell turnover [2]. However, the
- 51 proportion of cell-types and tissues contributing to cfDNA changes in the context of certain
- 52 physiological conditions or disease processes [3,4]. Thus, signals in cfDNA might serve as relevant
- 53 biomarkers in health and disease. Collecting cfDNA in so-called liquid biopsies (Fig. 1) is considered
- 54 non-invasive and led to an increased research interest in the biomedical field for using cfDNA in 55 allograft (i.e., donor organ) rejection, prenatal testing and diagnostics, as well as disease detection and
- 56 health monitoring [5] (especially for cancer).
- 57 Over the last years, many approaches have been developed to extract information from cfDNA samples
- 58 for various applications. Methods range from identifying allelic differences at known disease markers,
- 59 detection and tracking of mutations [6] and copy number alterations (CNAs) in tumor cells [6], and DNA
- fragmentation differences [3,8,9] to measuring methylation state [10–12]. While these methods
- 61 exploit different signals, all rely on the precise quantification of read distributions, and slight changes
- 62 in read recovery affect their results (Fig. 1).
- Therefore, consistent data quality is the primary requirement for developing these new diagnostic methods (Fig. 1). Even though sample handling is constantly streamlined, individual differences of
- 64 methods (Fig. 1). Even though sample handling is constantly streamlined, individual differences of 65 sample donors, and logistic factors like time of sample collection, duration, conditions of storage, and
- further preanalytical handling are challenging to fully control in a clinical context, but have been shown
- to affect the quality of cfDNA samples [13–16]. Additionally, detecting signals of interest (e.g., from
- 68 circulating tumor DNA, ctDNA) in a background mainly derived from hematopoietic cells [16] is not
- 69 trivial, emphasizing the need for optimal data quality.
- 70 One way to mitigate some preanalytical effects and technical biases introduced during sequencing of
- cfDNA samples is to include specialized correction and sampling steps during computational processing
- 72 of the data (Fig. 1). Even though the need has been identified previously in the field of cfDNA,
- 73 community standards are still lacking for preprocessing genome sequencing data from cfDNA [7,8,18–
- 74 23].



#### 75

Figure 1: Overview of cfDNA analysis. The leftmost panel depicts data generation by liquid biopsy sampling followed by library
 preparation and sequencing. The second panel shows the entry point of cfDNA Uniflow. It displays the core functionality of
 merging reads/removing adapters, length filtering, mapping to a reference genome and duplicate marking. Sample quality
 control is shown in the third panel and for example performed using FastQC, Mosdepth and SAMtools stats. The fourth panel
 shows optional steps of GC bias correction and estimation of copy number alterations and tumor proportion. Finally, results
 are aggregated, for example in a report and used for downstream analyses (fifth panel). Figure created with Biorender.

82 One reason for the lack of dedicated cfDNA pipelines, might be that many publications in the field are focused on the downstream analysis like the classification of disease samples, relying on unpublished 83 84 in-house pipelines for data processing. Further, important correction steps are often tailored towards 85 specific features and tightly integrated in downstream analysis pipelines, making it difficult to 86 generalize and transfer them to new projects [7,8]. Nevertheless, there have been some approaches 87 trying to address the need for community standards. A notable one is the FinaleDB project, which 88 aggregates cfDNA samples from multiple sources, processes them in a uniform manner and provides 89 fragment coordinates via a web portal [23]. To protect the privacy of patients, the data is anonymized 90 during processing, removing all sequence information and making it unsuitable for analyses not 91 focused on fragmentation patterns. Additionally, this pipeline does not address issues of batch and 92 bias correction, which might be most relevant in such aggregation efforts. The project getting closest 93 to setting a community standard for processing samples not just for fragmentomics applications, is 94 called cfDNApipe. It combines many useful tools for basic processing of normal and bisulfite converted 95 DNA sequences. The utility functions range from generation of summary statistics, GC-bias correction 96 tailored towards CNV detection and extraction of a limited number of features [25]. However, the 97 software seems to be designed for single computer use, lacking many of the features provided by a 98 full-fledged workflow management system, making it hard to scale analysis in different environments, 99 like compute clusters. Moreover, the design does not allow for easy integration of new functionalities, 100 creating the need for either an additional workflow management system or extensive modification of 101 the original code.

102 Technical biases and missing community standards cause several drawbacks for the field. First, users 103 rely on standard processing pipelines from other fields, which might not be suitable for specific 104 analyses. They might also feel the need to develop their own pipelines by selecting appropriate tools 105 and tuning parameters optimized on the available set of samples. Second, it adds additional overhead when comparing across multiple studies. Here, researchers are frequently required to work with the 106 107 original processing of each site, potentially introducing technical biases in the analysis. Alternatively, reprocessing data from multiple sites can reduce technical biases between studies but creates an 108 109 additional computational and organizational burden (incl. access to raw and protected genetic data). 110 Third, it can be hard to keep track of all sample-level information when building analysis pipelines using 111 many samples, mainly when information gets scattered across many samples and files. 112 To jointly address several of these problems, we developed an easy-to-use unified preprocessing

workflow for cell-free DNA written in Snakemake. It combines a curated list of tools for processing genomic cfDNA samples, custom tools for reducing technical biases, and tools for estimating additional characteristics like copy number states. Our pipeline is implemented with high configurability, scalability from single computers to high-performance compute clusters, and a sophisticated reporting system.

## 119 Overview and implementation

#### 120 Implementation

121 We implemented the cfDNA UniFlow workflow in the popular workflow management system

- 122 Snakemake [25]. This makes it easy to scale the workflow in different computing environments and
- allows for parallel processing of multiple samples. Further, most of the rules are implemented to
- enable multiprocessing and efficiently utilize multiple cores for each task. Conveniently, default
- resources like genome references or standard adapter files can be downloaded, if not configured to
- point to already available resources. A detailed overview of the workflow is available in Figure S1.
- 127 Briefly, cfDNA UniFlow covers three parts between data generation and downstream analysis: data pre-
- 128 processing, quality control and utility functions (Figure 1).



129

- 130 Figure 2: Overview of unified cfDNA preprocessing workflow. Functionalities are color coded by task. Blue boxes contain the
- 131 core functionality of cfDNA Uniflow. Red boxes represent rules for the automatic download of public resources. Yellow boxes
- summarize the Quality Control and reporting steps. Finally, grey and green boxes are optional steps, with green boxes being
   highly recommended.

#### 134

#### 135 Preprocessing

136 The core preprocessing steps (Fig 2., components depicted in blue) expect FASTQ files as input.

- Alternatively, existing alignments (BAM files) can be provided for reprocessing. In the latter case, the
- workflow automatically converts these to FASTQ files using SAMtools [26]. Afterwards, reads can be
- 139 merged with NGmerge [27], which also removes sequencing library adapters and corrects sequencing
- 140 errors and ambiguous bases based on the read-overlap consensus. Reads that were not merged, can

- 141 be postprocessed using NG merge adapter removal mode and can be included in the mapping process.
- 142 Alternatively, the merging step can be skipped and reads will only be trimmed using Trimmomatic.
- 143 Prior to mapping with bwa-mem2 [29], reads are further filtered based on their length, excluding reads
- 144 that are shorter than a configurable threshold. Finally, duplicate reads are marked (SAM tools markdup)
- 145 before the BAM files of the samples are passed to the next step.

#### 146 Quality Control

- 147 In the Quality control (QC) step (Fig. 2, components depicted in yellow), general post-alignment 148 statistics and graphs are calculated for each sample with SAMtools stats [26] and FastQC [30].
- Additional information on sample-wide median coverage and coverage at different genomic regions is
- 150 calculated via Mosdepth [31]. The QC results are aggregated in an HTML report via MultiQC [32] and
- 151 an example is shown Figure S2.

## 152 Signal Extraction

In the last step, additional utility modules (Fig. 2, components depicted in green) can be configured 153 154 and executed. This includes our in-house GC bias estimation and correction methods 155 (https://github.com/kircherlab/cfDNA GCcorrection), an extension of the method described by 156 Benjamini & Speed [17]. As fragmentation in cfDNA is driven by natural degradation processes, libraries 157 constructed from liquid biopsies tend to have fragments of a wide range of lengths and do not follow 158 the original assumption that length is well-approximated by the mean fragment length. Therefore, we 159 estimate the expected fragment distribution by sampling regions along the reference genome, 160 counting all possible fragments for a specified range of fragment lengths and sorting them in bins of 161 their GC content. Afterwards, we measure the sample specific fragment distribution in the same 162 regions, scale them and compare them to the theoretical distribution. Based on the ratio of observed 163 and expected, we calculated correction values for each fragment length and GC content. The resulting 164 weights are attached to the reads as tags, which can be used for a wide variety of downstream signal extraction methods, while preserving the original read coverage and fragmentation patterns. We 165 166 provide specialized signal extraction routines to extract coverage derived signals using read weights. Further, we included the widely used tool ichorCNA [6], to identify copy number alterations and 167 168 estimate tumor fraction. An example of the output is available in Figure S3.

## 169 Reporting

170 Finally, all information provided by the previous steps is aggregated in a comprehensive HTML report.

- 171 This includes summary statistics on workflow execution provided by Snakemake, and plots and
- summary statistics produced in the quality control steps. Additional information from optional steps
- includes a general estimation of sample-specific GC bias parameters (Figure S4), the effects of GC bias
- 174 correction in user defined regions (Figure S5) and plots on copy number alterations created by
- ichorCNA. Finally, case-control plots are generated and included, if more than one class of samples is
- 176 provided (Figure S6).

## 177 Results

To test and showcase cfDNA Uniflow, we use three exemplary cfDNA samples (healthy H01, breast 178 179 cancer B01, prostate cancer P01) with different conditions and average GC contents from the European 180 Genome-Phenome Archive Study EGAS00001006963. Each sample was converted to FASTQ files and 181 processed in our pipeline with standard parameters for human reference build GRCh38/hg38. As user-182 defined regions of interest, we selected 10,000 binding sites of LYL1, a transcription factor (TF) associated with hematopoietic cells [33], and GRHL2, an important pioneer TF for epithelial cells [34-183 184 36] playing a role in a wide variety of cancer types [37–41]. Both TFs are especially suited due to their 185 association with expected tissue contributions in our samples and because they have high GC content 186 binding sites.

187 This can be seen in Figure 3, which shows coverage overlays centered on LYL1 binding sites and illustrates the global and regional effects of GC biases in the respective samples. The healthy sample 188 189 H01, with an average GC content of 45%, shows a balanced global GC profile (Fig. 3a) and, accordingly, 190 the GC bias correction shows almost no effects on the composite signal. We see the strongest drop of 191 coverage at the TF binding site, expected for a sample of mainly hematopoietic origin where many 192 LYL1 binding sites are expected to be accessible to the TF. B01, a breast cancer sample with an average 193 GC content of 38%, shows an overrepresentation of fragments with GC content lower than the genome 194 average and an underrepresentation of fragments with higher GC content (Fig. 3b). This leads to a 195 distortion of the composite coverage signal around the LYL1 binding sites. Without GC correction, the drop in coverage would be overestimated. After correction, coverage at the site is closer to the 196 197 coverage of the surrounding regions, consistent with an expected signal dilution compared to the 198 healthy sample (Fig. 3a) due to a higher contribution of non-hematopoietic cell-types in this cancer 199 sample (Fig. 3b). The same should be true for sample P01 (Fig. 3c), a prostate cancer sample with an 200 average GC content of 45%. However, the global GC bias profile (right panels) show the inverse trend 201 to sample B01, with a shift of fragment distribution towards a higher GC content. Unsurprisingly, the 202 signal around the binding sites is distorted towards higher coverage prior to the GC correction (i.e., 203 suggesting that the TF binding sites are not accessible). After GC correction, the signal looks similar to 204 the one shown for B01, less open than the healthy sample and consistent with an increased 205 contribution of non-hematopoietic cell-types. Global effects of GC bias correction on fragment 206 distribution and a comparison to two other fragment-based are provided in the Supplement (Figure 207 S7).



208

209 Figure 3: Effects of GC bias on regional and global scale. Composite coverage signals of 10,000 LYL1 transcription factor 210 binding sites (left) and global bias profiles (right) for three cfDNA samples are shown. a) Signals and profile for a healthy 211 sample (H01) with an average GC content of 41%. The GC profile (right) is relatively balanced between observed and expected 212 fragments. Respectively, the GC bias corrections have only minor effects on the composite coverage signal (left). b) GC bias 213 effects for a breast cancer sample with an average GC content of 38%. The global GC profile shows an overrepresentation of 214 lower GC content fragments (brighter color) and an underrepresentation of higher GC content fragments (darker color). This 215 results in an underestimation of coverage (overestimation of accessibility) at the LYL1 binding sites. After GC correction the 216 signal is closer to the surrounding coverage, consistent with lower relative contributions of hematopoietic cells and fewer open 217 sites. In contrast, c) shows the GC bias effects of a prostate cancer cell with an average GC content of 45%. The global GC 218 profile is skewed towards a higher GC content, leading to an overestimation of coverage around the LYL1 binding sites. After 219 GC correction, the signal is closer to the surrounding coverage, indicating lower contributions of hematopoietic cells with 220 accessible LYL1 sites.

In addition to the GC bias plots for individual samples, we provide case-control plots for comparing sample classes with a control in the same plot. In our example, the healthy sample H01 would be the control and we are comparing samples on the LYL1 and GRHL2 sites. As noted, the expected signal around LYL1 binding sites is a drop in coverage for samples mainly derived from hematopoietic cells. When the contribution of non-hematopoietic cell-types, in which LYL1 is not expressed, increases, we expect to see a relative increase in coverage around the binding sites. Accordingly, the signals shown for our three test samples (Fig. 4a) are in line with that expectation. For GRHL2, we expect the opposite signal. As healthy samples should not include many contributions from tissues with high GRHL2
 activity, the expected coverage signal should be similar to the surrounding regions. In contrast, samples
 with high contributions of cancer-derived DNA should show a drop in coverage, indicative of higher
 accessibility of the TF binding sites (Fig. 4b).





233 Figure 4: Case-control plots around GRHL2 and LYL1 binding sites. a) GC corrected composite coverage signals around 10,000 234 centered LYL1 transcription factor binding sites. The healthy sample (H01) shows lower relative coverage (i.e., higher 235 accessibility) at the center of the binding site overlay. This is consistent with higher LYL1 activity in hematopoietic cells. In 236 contrast, both cancer samples show higher relative coverage in the central region, in line with a higher proportion of non-237 hematopoietic cells contributing to the signal. b) Composite coverage signals around 10,000 GRHL2 binding sites after GC 238 correction. Both cancer samples show a lower central coverage compared to surrounding regions (i.e., higher accessibility), 239 indicating higher activity than in the healthy sample. This is consistent with GRHL2 expression being associated with different 240 cancers.

As pointed out before, exemplary figures of the other report sections, like QC or ichorCNA, can be found in the supplement (Figures S2-S6). The full example report can be found in our GitHub repository.

244

#### 245 Conclusion

Here we propose cfDNA UniFlow, a unified preprocessing pipeline specifically tailored for cfDNA samples. It is an easy-to-use, scalable, and configurable workflow, aiming to set a community standard for enabling accessible and easily sharable future research in the field. In designing our workflow, we aimed at providing a tool that can be used without much computer science background, but with the option to be easily extended by experienced users with their own custom modules, allowing its

extension from a standard processing workflow to a full-featured analysis pipeline.

## 252 Availability and Requirements

- 253 Project name: cfDNA-UniFlow
- 254 Project home page: https://github.com/kircherlab/cfDNA-UniFlow
- 255 Operating system(s): Linux (64-bit)
- 256 Programming language: Python
- 257 Other requirements: Mamba or Conda
- 258 License: MIT

#### 259

# 260 Additional Files

Supplementary Note: A general overview of the workflow including Supplementary Figures and aquick start guide.

- Supplementary Figure 1: A detailed overview of the workflow components.
- Supplementary Figure 2: Example section of a QC report.
- Supplementary Figure 3: Example report for ichorCNA plot of copy number alterations.
- Supplementary Figure 4: Example of a sample's global GC bias estimate.
- Supplementary Figure 5: Example report of regional effects of GC bias correction.
- Supplementary Figure 6: Example of a case-control plot.
- Supplementary Figure 7: Comparison of three fragment based GC correction methods.
- 270

### 271 Abbreviations

- 272 BAM: binary alignment map; cfDNA: cell-free DNA; CNA: copy number alteration; ctDNA: circulating
- 273 tumor DNA; TF: transcription factor; QC: quality control
- 274

### 275 Data Availability

276 The data used for generating plots included in this article are available in the European Genome-

- 277 Phenome Archive at <u>https://ega-archive.org</u> with accession <u>EGAD00001010100</u>.
- 278

## 279 Acknowledgements

We thank current and previous members of the Kircher and Speicher laboratories for helpful discussions and suggestions. Computation has been performed on the HPC for Research cluster of the

282 Berlin Institute of Health at Charité – Universitätsmedizin Berlin.

283

## 284 Author contributions

Conceptualization: S.R., M.K. and M.R.S.; Data curation: S.R.; Formal analysis: S.R.; Funding acquisition:
M.K.; Methodology: S.R.; Project administration: M.K.; Resources: M.K. and M.R.S.; Software: S.R.;
Supervision: M.K.; Validation: S.R. and L.B.; Visualization: S.R.; Writing – original draft: S.R.; Writing -

288 review & editing: S.R., L.B., M.R.S. and M.K.

289

- 290 Conflict of interest
- 291 None declared.

#### 293 References

Chan AKC, Chiu RWK, Lo YMD, Clinical Sciences Reviews Committee of the Association of Clinical
 Biochemists. Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis.
 *Ann Clin Biochem*. 2003; doi: 10.1258/000456303763046030.

297 2. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from
298 maternal plasma. *Am J Hum Genet*. 1999; doi: 10.1086/302205.

3. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an In Vivo
Nucleosome Footprint that Informs Its Tissues-Of-Origin. *Cell*. 2016; doi: 10.1016/j.cell.2015.11.050.

4. Ulz P, Perakis S, Zhou Q, Moser T, Belic J, Lazzeri I, et al.. Inference of transcription factor binding
 from cell-free DNA enables tumor subtype prediction and early detection. *Nat Commun*. Nature
 Publishing Group; 2019; doi: 10.1038/s41467-019-12714-4.

5. Ding SC, Lo YMD. Cell-Free DNA Fragmentomics in Liquid Biopsy. *Diagn Basel Switz*. 2022; doi:
 10.3390/diagnostics12040978.

306 6. Tunc I, Agbor-Enoh S, Valantine H, Thein SL, Pirooznia M. Cfcloud: A Cloud-Based Workflow for
 307 Cell-Free DNA Data Analysis. *Blood*. 2020; doi: 10.1182/blood-2020-138785.

308 7. Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al.. Scalable whole acome sequencing of cell-free DNA reveals high concordance with metastatic tumors. *Nat Commun.*2017; doi: 10.1038/s41467-017-00965-y.

8. Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chicard M, et al.. Multimodal analysis of
cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. *Nat Commun*. 2021; doi: 10.1038/s41467-021-23445-w.

9. Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al.. Genome-wide cell-free DNA
fragmentation in patients with cancer. *Nature*. 2019; doi: 10.1038/s41586-019-1272-6.

10. Erger F, Nörling D, Borchert D, Leenen E, Habbig S, Wiesener MS, et al.. cfNOMe — A single assay
for comprehensive epigenetic analyses of cell-free DNA. *Genome Med*. 2020; doi: 10.1186/s13073020-00750-5.

- Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al.. Sensitive
   tumour detection and classification using plasma cell-free DNA methylomes. *Nature*. Nature
   Publishing Group; 2018; doi: 10.1038/s41586-018-0703-0.
- 12. Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, et al.. The cell-free DNA methylome captures
  distinctions between localized and metastatic prostate tumors. *Nat Commun*. Nature Publishing
  Group; 2022; doi: 10.1038/s41467-022-34012-2.
- Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in
   serum and plasma during storage of blood samples. *Clin Chem*. 2003; doi: 10.1373/49.6.1028.
- 14. Lampignano R, Neumann MHD, Weber S, Kloten V, Herdean A, Voss T, et al.. Multicenter
   Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of
   Standardized (Pre)analytical Work Flows. *Clin Chem*. 2020; doi: 10.1373/clinchem.2019.306837.

15. Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R, et al.. The Effect of Preservative
 and Temperature on the Analysis of Circulating Tumor DNA. *Clin Cancer Res Off J Am Assoc Cancer*

332 Res. 2017; doi: 10.1158/1078-0432.CCR-16-1691.

16. van Dessel LF, Beije N, Helmijr JCA, Vitale SR, Kraan J, Look MP, et al.. Application of circulating
 tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions. *Mol Oncol.* 2017; doi: 10.1002/1878-0261.12037.

17. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al.. Phylogenetic
 ctDNA analysis depicts early stage lung cancer evolution. *Nature*. 2017; doi: 10.1038/nature22364.

18. Benjamini Y, Speed TP. Summarizing and correcting the GC content bias in high-throughput
 sequencing. *Nucleic Acids Res*. 2012; doi: 10.1093/nar/gks001.

19. Kim CS, Mohan S, Ayub M, Rothwell DG, Dive C, Brady G, et al.. In silico error correction improves
 cfDNA mutation calling. *Bioinformatics*. 2019; doi: 10.1093/bioinformatics/bty1004.

20. Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, et al.. Inferring gene
expression from cell-free DNA fragmentation profiles. *Nat Biotechnol*. Nature Publishing Group;
2022; doi: 10.1038/s41587-022-01222-4.

21. Doebley A-L, Ko M, Liao H, Cruikshank AE, Santos K, Kikawa C, et al.. A framework for clinical
cancer subtyping from nucleosome profiling of cell-free DNA. *Nat Commun*. 2022; doi:
10.1038/s41467-022-35076-w.

22. Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, et al.. Detection and
characterization of lung cancer using cell-free DNA fragmentomes. *Nat Commun*. 2021; doi:
10.1038/s41467-021-24994-w.

23. Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, et al.. Evaluation of
 pre-analytical factors affecting plasma DNA analysis. *Sci Rep*. 2018; doi: 10.1038/s41598-018-25810 0.

24. Zheng H, Zhu MS, Liu Y. FinaleDB: a browser and database of cell-free DNA fragmentation
 patterns. *Bioinformatics*. Oxford University Press; 2021; doi: 10.1093/bioinformatics/btaa999.

25. Zhang W, Wei L, Huang J, Zhong B, Li J, Xu H, et al.. cfDNApipe: a comprehensive quality control
and analysis pipeline for cell-free DNA high-throughput sequencing data. *Bioinformatics*. 2021; doi:
10.1093/bioinformatics/btab413.

- 359 26. Mölder F, Jablonski KP, Letcher B, Hall MB, Tomkins-Tinch CH, Sochat V, et al.. Sustainable data
   360 analysis with Snakemake. F1000Research;
- 27. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al.. Twelve years of SAMtools
   and BCFtools. *GigaScience*. 2021; doi: 10.1093/gigascience/giab008.
- 363 28. Gaspar JM. NGmerge: merging paired-end reads via novel empirically-derived models of
   364 sequencing errors. *BMC Bioinformatics*. 2018; doi: 10.1186/s12859-018-2579-2.
- 29. Vasimuddin Md, Misra S, Li H, Aluru S. Efficient Architecture-Aware Acceleration of BWA-MEM
   for Multicore Systems. 2019 IEEE Int Parallel Distrib Process Symp IPDPS.
- 30. Andrews S. FASTQC. A quality control tool for high throughput sequence data.

368 31. Pedersen BS, Quinlan AR. Mosdepth: quick coverage calculation for genomes and exomes.
 369 *Bioinformatics*. 2018; doi: 10.1093/bioinformatics/btx699.

- 370 32. Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: summarize analysis results for multiple tools
   371 and samples in a single report. *Bioinformatics*. 2016; doi: 10.1093/bioinformatics/btw354.
- 372 33. Zohren F, Souroullas GP, Luo M, Gerdemann U, Imperato MR, Wilson NK, et al.. The transcription
   373 factor Lyl-1 regulates lymphoid specification and the maintenance of early T lineage progenitors. *Nat* 374 *Immunol*. Nature Publishing Group; 2012; doi: 10.1038/ni.2365.
- 34. Jacobs J, Atkins M, Davie K, Imrichova H, Romanelli L, Christiaens V, et al.. The transcription factor
   Grainy head primes epithelial enhancers for spatiotemporal activation by displacing nucleosomes.
   Nat Canet Nature Publishing Groups 2018: doi: 10.1028/c41588.018.0140 x
- 377 *Nat Genet*. Nature Publishing Group; 2018; doi: 10.1038/s41588-018-0140-x.
- 378 35. Chen AF, Liu AJ, Krishnakumar R, Freimer JW, DeVeale B, Blelloch R. GRHL2-Dependent Enhancer
  379 Switching Maintains a Pluripotent Stem Cell Transcriptional Subnetwork after Exit from Naive
  380 Pluripotency. *Cell Stem Cell*. 2018; doi: 10.1016/j.stem.2018.06.005.
- 381 36. Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, et al.. The Lineage
- Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine
   Therapy-Resistant Breast Cancer. *Cell Rep.* 2019; doi: 10.1016/j.celrep.2019.09.032.
- 37. Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I, et al.. Novel Androgen Receptor
   Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. *Cancer Res.* 2017; doi: 10.1158/0008-5472.CAN-16-1616.
- 387 38. Riethdorf S, Frey S, Santjer S, Stoupiec M, Otto B, Riethdorf L, et al.. Diverse expression patterns
  388 of the EMT suppressor grainyhead-like 2 (GRHL2) in normal and tumour tissues. *Int J Cancer*. 2016;
  389 doi: 10.1002/ijc.29841.
- 390 39. Reese RM, Harrison MM, Alarid ET. Grainyhead-like Protein 2: The Emerging Role in Hormone 391 Dependent Cancers and Epigenetics. *Endocrinology*. 2019; doi: 10.1210/en.2019-00213.
- 40. Kwan EM, Fettke H, Crumbaker M, Docanto MM, To SQ, Bukczynska P, et al.. Whole blood GRHL2
  expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant
  prostate cancer. *Transl Androl Urol*. AME Publishing Company; 2021; doi: 10.21037/tau-20-1444.
- 41. Kumegawa K, Takahashi Y, Saeki S, Yang L, Nakadai T, Osako T, et al.. GRHL2 motif is associated
- 396 with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. *Npj Breast Cancer*.
- 397 Nature Publishing Group; 2022; doi: 10.1038/s41523-022-00438-6.
- 398













